Pseudomonas aeruginosa infections in the intensive care unit

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 1, 2003, Pages 61-68

  Quinn, John P ^a,b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY   (United States)

Author keywords

ICU infections; Pathogenesis; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBENICILLIN; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GATIFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEZLOCILLIN; MOXIFLOXACIN; NETILMICIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BACTERIAL VIRULENCE; BIOFILM; CELL KILLING; COLONY FORMATION; DRUG TARGETING; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INTRACELLULAR KILLING; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 0037325807     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37917     Document Type: Review

References (64)

1. Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC. Color Atlas and Textbook of Diagnostic Microbiology. 5th ed. Philadelphia: Lippincott; 1997:257-269
2. Forkner CE. Pseudomonas aeruginosa infections. In: Wright IS, ed. New York and London: Grune and Stratton; 1960:1-5. Modern Medical Monographs No. 22
3. Stratton CW. Pseudomonas aeruginosa revisited. Infection Control Hosp Epidemiol 1990;11:101-104
4. Pollack, M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Philadelphia: Churchill Livingstone; 2000:2310-2335
5. Neu HC. The role of Pseudomonas aeruginosa in infections. J Antimicrob Chemother 1983;11:1-13
6. Rello J, Jubert P. Evaluation of outcome for intubated patients with pneumonia due to Pseudomonas aeruginosa. Clin Infect Dis 1996;23:973-978
7. Kush BJ, Hoadley AW. A preliminary survey of the association of Pseudomonas aeruginosa with commercial whirlpool bath waters. Am J Public Health 1980;70:279-281
8. Gould IM, Wise R. Pseudomonas aeruginosa: clinical manifestation and management. Lancet 1985;2:1224-1227
9. Olson B, Weinstein RA, Nathan C, et al. Epidemiology of Endemic Pseudomonas aeruginosa: why infection control efforts have failed. J Infect Dis 1984;150:808-816
10. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. Crit Care Med 1999;27:887-893
11. Doig P, Todd T. Role of pili in adhesion of Pseudomonas aeruginosa to human respiratory epithelial cells. Infect Immun 1988;56:1641-1646
12. Baker NR, Minor V, Deal C, et al. Pseudomonas aeruginosa exoenzyme S is an adhesin. Infect Immun 1991;59:2859-2863
13. Cross AS, Sadoff JC, Iglewski FH, et al. Evidence of the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis 1980;142:538-546
14. Nicas TI, Bradley J, Lochner JE, et al. The role of exoenzyme S in infections with Pseudomonas aeruginosa. J Infect Dis 1985;152:716-721
15. Govan JRW, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-574
16. Wilson R, Dowling RB. Pseudomonas aeruginosa and other related species. Thorax 1998;53:213-219
17. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999;284:1318-1322
18. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc 1999;74:187-195
19. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416:740-743
20. Morihara K. Production of elastase and proteinase by Pseudomonas aeruginosa. J Bacteriol 1964;88:745-757
21. Parmely M, Gale A, Clabaugh M, et al. Proteolytic inactivation of cytokines by Pseudomonas aeruginosa. Infect Immun 1990;58:3009-3014
22. Bishop MB, Baltch AL, Hill LA, et al. The effect of Pseudomonas aeruginosa cytotoxin and toxin A on human polymorphonuclear leukocytes. J Med Microbiol 1987;24:315-324
23. Berka RM, Vasil ML. Phospholipase c (heat-labile hemolysin) of Pseudomonas aeruginosa: purification and preliminary characterization. J Bacteriol 1981;152:239-245
24. Johnson MK, Boese-Marrazzo D. Production and properties of heat-stable extracellular hemolysin from Pseudomonas aeruginosa. Infect Immun 1980;29:1028-1033
25. Pollack M, Young LS. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest 1979;63:276-285
26. Neuhauser M, Itokazu G, Karon G, Weinstein RA, Quinn JP. Increasing resistance to quinolones and ceftazidime among gram-negative isolates from ICU patients [abstract #86]. Infectious Disease Society of America meeting, New Orleans, September 2000
27. Burwen DR, Banerjee SN, Gaynes RP, et al. Ceftazidime resistance among selected gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis 1994;170:1622-1625
28. Jacobsen KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995;21:1107-1113
29. Manian FA, Meyer L, Jenne J, et al. Loss of antimicrobial susceptibility in aerobic gram-negative bacilli repeatedly isolated from patients in intensive-care units. Infect Control Hosp Epidemiol 1996;17:222-226
30. Harris A, Torres-Viera C, Venktatraman V, et al. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128-1133
31. Carmeli Y, Troillet N, Eliopoulos GM, et al. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-1382
32. Fink MP, Torres-Viera C, Venkataraman L, et al. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastin. Antimicrob Agents Chemother 1994;38:547-557
33. Zabner R, Quinn JP. Antimicrobials in cystic fibrosis: emergence of resistance and implications for treatment. Semin Resp Infect 1992;7:210-217
34. Hitt CM, Nightingale CH, Quintiliani R, et al. Streamlining antimicrobial therapy for lower respiratory tract infections. Clin Infect Dis 1997;24(suppl 2):S231-S237
35. Consensus statement: hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care Med 1996;153:1711-1725
36. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-546
37. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997;41:1127-1133
38. Isenberg HD, Alperstein P, France K. In vitro activity of ciprofloxacin, levofloxacin, and trovafloxacin, alone and in combination with β-lactams, against clinical isolates of Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Burkholderia cepacia. Diag Microbiol Infect Dis 1999;33:81-86
39. Iaconis JP, Pitkin DH, Sheik W, et al. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Clin Infect Dis 1997;24(suppl 2):S191-S196
40. Odenholt I. Ertapenem: a new carbapenem. Expert Opin Investig Drugs 2001;10:1157-1166
41. Quinn JP, Studemeister AE, DiVencenzo CA, et al. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis 1988;10:892-898
42. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investig Drugs 2002;3:218-224
43. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002;34:634-640
44. Hellinger WC, Brewer NS. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999;74:420-434
45. Rubin BK. Emerging therapies for cystic fibrosis lung disease. Chest 1999;115:1120-1126
46. Edson RS, Terell CL. The aminoglycosides. Mayo Clin Proc 1999;74:519-528
47. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-1011
48. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998;27(suppl 1):S93-S99
49. Hancock RE, Bellido F. Antibacterial in vitro activity of fourth-generation cephalosporins. J Chemother 1996;8(suppl 2):S31-S36
50. Fung-Tomc JC, Gradelski E, Huczko E, et al. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:1289-1293
51. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: Respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999;43:524-427
52. Masuda N, Sakagawa E, Ohya S. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1995;39:645-649
53. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000;46:959-964
54. Bryan LE, O'Hara K, Wong S. Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984;26:250-255
55. Yoshida H, Nakamura M, Bogaki M, et al. Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:1273-1275
56. Poole K, Krebes K, McNally C, et al. Multiple antibiotic resistance in Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J Bacteriol 1993;175:7363-7372
57. Ma D, Cook DN, Hearst JE, et al. Efflux pumps and drug resistance in gram-negative bacteria. Trends Microbiol 1994;2:489-493
58. McCall CY, Spruill WJ. The use of aerosolized tobramycin in the treatment of a resistant pseudomonal pneumonitis. Ther Drug Monitor 1989;11:692-695
59. McCarthy M. Inhaled antibiotics effective for cystic fibrosis. Lancet 1999;353:215
60. Ramsey BW, Dorkin HL. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-1746
61. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30
62. Nelson S, Belknap SM. A randomized controlled trial of filgrastim as an adunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998;178:1075-1080
63. Knapp B, Hundt E, Lenz, et al. A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa. Vaccine 1999;17:1663-1666
64. Mansouri E, Gabelsberger J, Knapp B, et al. Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-1 vaccine in human volunteers. Infect Immun 1999;67:1461-1470